Cladribine tablets coming of age: expert views on the impact of the new label for patients with MS and the NHS

Cladribine tablets coming of age: expert views on the impact of the new label for patients with MS and the NHS

Cladribine tablets (CladT) were initially approved for use in people with highly active relapsing multiple sclerosis (RMS) in 2017. However, following review of the clinical development programme and subsequent long-term efficacy and safety data, the Medicines and Healthcare products Regulatory Agen...

Full description

Saved in:
Bibliographic Details
Main Authors: Tarunya Arun, Mavis Ayer, Wallace Brownlee, Nikos Evangelou, Niall MacDougall, Joela Mathews, Lesley Murray, Owen Pearson, Laura Wallace, Klaus Schmierer
Format: Article
Language:English
Published: Whitehouse Publishing 2025-06-01
Series:Advances in Clinical Neuroscience & Rehabilitation
Online Access:https://acnr.co.uk/articles/cladribine-tablets-coming-of-age-expert-views-on-the-impact-of-the-new-label-for-patients-with-ms-and-the-nhs/
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://acnr.co.uk/articles/cladribine-tablets-coming-of-age-expert-views-on-the-impact-of-the-new-label-for-patients-with-ms-and-the-nhs/

Similar Items